These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 35171029

  • 1. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
    Fu Y, Li X, Li Y, Lu W, Xie X, Wang X.
    Microbiol Spectr; 2022 Feb 23; 10(1):e0157021. PubMed ID: 35171029
    [Abstract] [Full Text] [Related]

  • 2. Risk stratification for cervical precancer and cancer by DH3-HPV partial genotyping and cytology in women attending cervical screening: A retrospective cohort study.
    Fu Y, Li Y, Li X, Wang X, Lü W.
    J Med Virol; 2023 Feb 23; 95(2):e28482. PubMed ID: 36609841
    [Abstract] [Full Text] [Related]

  • 3. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X, Wu Q, Wang X, Fu Y, Zhang X, Tian X, Cheng B, Lu B, Yu X, Lan S, Lu W, Ma D, Cheng X, Xie X.
    Clin Microbiol Infect; 2018 Dec 23; 24(12):1322-1327. PubMed ID: 29518562
    [Abstract] [Full Text] [Related]

  • 4. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M, Oštrbenk A, Seme K, Šterbenc A, Jančar N, Vrtačnik Bokal E.
    J Clin Virol; 2016 Mar 23; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [Abstract] [Full Text] [Related]

  • 5. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.
    Vaccine; 2012 Nov 20; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [Abstract] [Full Text] [Related]

  • 6. Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework.
    Xu L, Padalko E, Oštrbenk A, Poljak M, Arbyn M.
    Int J Mol Sci; 2018 Sep 11; 19(9):. PubMed ID: 30208597
    [Abstract] [Full Text] [Related]

  • 7. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
    Xu L, Oštrbenk A, Poljak M, Arbyn M.
    J Clin Virol; 2018 Jan 11; 98():37-42. PubMed ID: 29241150
    [Abstract] [Full Text] [Related]

  • 8. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.
    Health Technol Assess; 2014 Apr 11; 18(23):1-196. PubMed ID: 24762804
    [Abstract] [Full Text] [Related]

  • 9. Aptima HPV Assay versus Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial.
    Cook DA, Smith LW, Law J, Mei W, van Niekerk DJ, Ceballos K, Gondara L, Franco EL, Coldman AJ, Ogilvie GS, Jang D, Chernesky M, Krajden M.
    J Clin Virol; 2017 Feb 11; 87():23-29. PubMed ID: 27988420
    [Abstract] [Full Text] [Related]

  • 10. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
    Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Smith JS.
    Gynecol Oncol; 2012 Apr 11; 125(1):175-80. PubMed ID: 22233689
    [Abstract] [Full Text] [Related]

  • 11. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
    Huijsmans CJ, Geurts-Giele WR, Leeijen C, Hazenberg HL, van Beek J, de Wild C, van der Linden JC, van den Brule AJ.
    BMC Cancer; 2016 Nov 28; 16(1):922. PubMed ID: 27894291
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M, Roelens J, Simoens C, Buntinx F, Paraskevaidis E, Martin-Hirsch PP, Prendiville WJ.
    Cochrane Database Syst Rev; 2013 Mar 28; 2013(3):CD008054. PubMed ID: 23543559
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
    Polman NJ, Oštrbenk A, Xu L, Snijders PJF, Meijer CJLM, Poljak M, Heideman DAM, Arbyn M.
    J Clin Microbiol; 2017 Dec 28; 55(12):3544-3551. PubMed ID: 29021152
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A, Šterbenc A, Seme K, Poljak M.
    J Clin Microbiol; 2019 Dec 23; 58(1):. PubMed ID: 31666369
    [Abstract] [Full Text] [Related]

  • 17. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
    Poljak M, Kovanda A, Kocjan BJ, Seme K, Jancar N, Vrtacnik-Bokal E.
    Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep 23; 18(3):94-103. PubMed ID: 19784522
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.
    Cook DA, Mei W, Smith LW, van Niekerk DJ, Ceballos K, Franco EL, Coldman AJ, Ogilvie GS, Krajden M.
    BMC Cancer; 2015 Dec 16; 15():968. PubMed ID: 26674353
    [Abstract] [Full Text] [Related]

  • 19. Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women.
    Ngou J, Gilham C, Omar T, Goumbri-Lompo O, Doutre S, Michelow P, Kelly H, Didelot MN, Chikandiwa A, Sawadogo B, Delany-Moretlwe S, Meda N, Costes V, Mayaud P, Segondy M.
    J Acquir Immune Defic Syndr; 2015 Feb 01; 68(2):162-8. PubMed ID: 25394189
    [Abstract] [Full Text] [Related]

  • 20. Development and validation of a new HPV genotyping assay based on next-generation sequencing.
    Yi X, Zou J, Xu J, Liu T, Liu T, Hua S, Xi F, Nie X, Ye L, Luo Y, Xu L, Du H, Wu R, Yang L, Liu R, Yang B, Wang J, Belinson JL.
    Am J Clin Pathol; 2014 Jun 01; 141(6):796-804. PubMed ID: 24838323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.